Aadi Bioscience Inc expected to post a loss of 65 cents a share - Earnings Preview
11/03/2024 12:53
* Aadi Bioscience Inc AADI.OQ AADI.O is expected to show
a
rise in quarterly revenue when it reports results on March 13
for the period ending December 31 2023
* The Pacific Palisades California-based company is
expected to
report a 19.2% increase in revenue to $6.293 million from $5.28
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Aadi Bioscience Inc is
for a
loss of 65 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $14.00, above its last closing price of $2.14.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.72 -0.72 -0.60 Beat 17.1
Jun. 30 2023 -0.61 -0.62 -0.67 Missed -7.7
Mar. 31 2023 -0.58 -0.58 -0.57 Beat 2.4
Dec. 31 2022 -0.71 -0.52 Beat 26.8
Sep. -0.74 -0.74 -0.68 Beat 8.4
30 2022
Jun. 30 2022 -0.74 -0.75 -0.87 Missed -16
Mar. 31 2022 -0.71 -0.71 -0.66 Beat 7.3
Dec. 31 2021 -0.67 -0.98 -0.77 Beat 21.6
This summary was machine generated March 11 at 12:53 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)